An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia
Publicatiedatum: 8 februari 2023 First-trimester prenatal treatment with glucocorticoid (GC) dexamethasone (DEX) in pregnancies at risk for classic congenital adrenal hyperplasia (CAH) is associated with ethical dilemmas. Though effective in reducing virilisation in girls with CAH, it entails exposure to high doses of GC in fetuses that do not benefit from the treatment. The current…

